Business Description
Herantis Pharma PLC
ISIN : FI4000087861
Compare
Compare
Traded in other countries / regions
HRTIS.FinlandHRPMF.USA IPO Date
2014-06-11Description
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson's disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 185.37 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.12 | |||||
| Interest Coverage | 7.33 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year FCF Growth Rate | 37.4 | |||||
| 3-Year Book Growth Rate | -31.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.52 | |||||
| 9-Day RSI | 51.34 | |||||
| 14-Day RSI | 51.06 | |||||
| 6-1 Month Momentum % | -17.65 | |||||
| 12-1 Month Momentum % | -30 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | |||||
| Quick Ratio | 3.39 | |||||
| Cash Ratio | 3.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.3 | |||||
| Shareholder Yield % | -3.17 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | 29.88 | |||||
| ROA % | 4.64 | |||||
| ROIC % | 10.63 | |||||
| ROCE % | 7.85 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.14 | |||||
| Price-to-Tangible-Book | 6.24 | |||||
| EV-to-EBIT | 74.67 | |||||
| EV-to-EBITDA | 74.67 | |||||
| EV-to-FCF | -4.91 | |||||
| Price-to-Net-Current-Asset-Value | 6.24 | |||||
| Price-to-Net-Cash | 6.52 | |||||
| Earnings Yield (Greenblatt) % | 1.34 | |||||
| FCF Yield % | -16.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Herantis Pharma PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.007 | ||
| Beta | 0.44 | ||
| Volatility % | 24.25 | ||
| 14-Day RSI | 51.06 | ||
| 14-Day ATR (€) | 0.051749 | ||
| 20-Day SMA (€) | 1.4315 | ||
| 12-1 Month Momentum % | -30 | ||
| 52-Week Range (€) | 1.17 - 2.2 | ||
| Shares Outstanding (Mil) | 20.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Herantis Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Herantis Pharma PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Herantis Pharma PLC Frequently Asked Questions
What is Herantis Pharma PLC(OHEL:HRTIS)'s stock price today?
The current price of OHEL:HRTIS is €1.44. The 52 week high of OHEL:HRTIS is €2.20 and 52 week low is €1.17.
When is next earnings date of Herantis Pharma PLC(OHEL:HRTIS)?
The next earnings date of Herantis Pharma PLC(OHEL:HRTIS) is 2024-08-22.
Does Herantis Pharma PLC(OHEL:HRTIS) pay dividends? If so, how much?
Herantis Pharma PLC(OHEL:HRTIS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers